China Investment Roundup: A Summer Of Cross-Border Transactions

It was a busy summer for Chinese pharmaceutical companies and investors who went global shopping, eying mega acquisition deals since China announced plans to accept overseas clinical trial data and global multicenter studies as part of its policies.